Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03407625
Other study ID # STU 092016-026
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date May 13, 2019

Study information

Verified date October 2020
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Induction of labor is associated with increased cesarean delivery rates, particularly in women with an unfavorable cervix. Both pharmacologic and mechanical methods are utilized for cervical ripening and labor induction. Evidence on the safety and effectiveness of various mechanical and pharmacologic methods of cervical ripening and labor induction is abundant, and yet the majority of clinical trials evaluate time to delivery, rather than mode of delivery. This is a prospective, cluster-randomized clinical trial to compare a standard method of induction at our institution (oral misoprostol) with an alternative, commonly used combination method of oral misoprostol and transcervical foley bulb in women with term pregnancies requiring induction of labor.


Description:

The purpose of this study is to determine whether the use of a transcervical foley catheter, in combination with the standard oral misoprostol regimen will result in a decreased primary cesarean delivery rate among women with a cervical dilation of 2 centimeters of less who require induction of labor at term. This study is not an FDA-regulated study: there is no intent to test the foley bulb under an FDA-regulated protocol. Likewise, there is no intent to submit the results of this study for a change in the labeling of the foley used for this study. This study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center, and by the Office of Research Administration at Parkland Health and Hospital System. This will be a prospective, cluster-randomized trial comparing two accepted methods of induction of labor at term among women who present for delivery at Parkland Hospital. Eligible participants will include nulliparous and multiparous women at 37 weeks gestation or greater, with a living, singleton fetus and no major fetal malformations, in cephalic presentation, with intact membranes, no prior uterine scar, who qualify for prostaglandin administration and who have a cervical dilation of 2 centimeters or less, measured at the level of the internal os. Patients with latex allergy, non-reassuring fetal status, HIV, active herpes outbreak, a prior uterine scar, or any contraindication to prostaglandins (including 4 or more painful contractions per 10 minutes prior to prostaglandin administration) will be excluded from participation in the study. Computer-generated cluster randomization will occur on a weekly basis for all study participants, to either the combination method of foley bulb plus oral misoprostol regimen (study group) or to oral misoprostol alone regimen (control). According to the randomization protocol each week, participants will be randomized to either the standard of care (oral misoprostol/control group) or standard of care plus foley bulb (study group). The study group will undergo placement of a 30 French foley catheter filled with 30-35cc sterile saline into the cervix in addition to the standard regimen of oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses, for patients who meet criteria for fetal well-being, and do not had more than 4 painful contractions in 10 minutes. Misoprostol will not be administered to patients who have progressed to active labor, defined as 4 centimeters cervical dilation. The control group will undergo induction with our current standard oral misoprostol protocol alone, administered as 100 micrograms given every 4 hours for a maximum of 2 doses. Both groups will receive oxytocin as indicated by current labor protocols at our institution. The primary outcome will be the rate of vaginal delivery. Secondary outcomes will include obstetric outcomes, maternal outcomes, and neonatal outcomes. Obstetric outcomes will include indication for induction, need for oxytocin, indication for cesarean delivery, time to active labor, time to delivery, labor analgesia, presence of chorioamnionitis, meconium-stained amniotic fluid, terbutaline use, tachysystole (defined as 6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer) or hyperstimulation syndrome (defined as tachysystole accompanied by fetal heart rate decelerations). Maternal outcomes will include estimated blood loss, transfusion requirement, postpartum fever, uterine rupture, and unplanned hysterectomy. Neonatal outcomes will include umbilical cord blood pH, 5-minute APGAR score, intubation or ventilation in the delivery room, neonatal sepsis, and admission to Neonatal Intensive Care Unit (NICU) admission.


Recruitment information / eligibility

Status Completed
Enrollment 2227
Est. completion date May 13, 2019
Est. primary completion date May 13, 2019
Accepts healthy volunteers No
Gender Female
Age group 10 Years and older
Eligibility Inclusion Criteria: - 37 weeks gestation or greater - Living, singleton fetus - No major fetal malformations - Cephalic presentation - No prior uterine scar - Intact fetal membranes - Qualifies for prostaglandin administration according to current Parkland protocol - Have a cervical dilation of 2 centimeters or less, measured at the level of the internal os - Have an indication for induction or attempted induction of labor according to Parkland protocol Exclusion Criteria: - latex allergy - non-reassuring fetal status - HIV - active herpes outbreak - Prior uterine scar - Contraindication to prostaglandins according to current Parkland protocol - Contraindication to vaginal delivery

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Foley bulb plus Oral Misoprostol
Although labeled "experimental" for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.
Oral Misoprostol
Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.

Locations

Country Name City State
United States Parkland Health and Hospital Systems Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Vaginal Delivery vaginal delivery at first induction at delivery
Secondary Time to Delivery Time (in hours) from start of induction agent to delivery at first induction from start of induction agent to time of delivery
Secondary Indication for Cesarean Delivery Among women delivered by cesarean, the indication for cesarean at delivery
Secondary Dose of Oxytocin Given (mcg or mg) Total dose of oxytocin given for induction as calculated by volume infused, concentration of solution and rate of infusion at delivery
Secondary Time With Foley Bulb in Place time (in hours) from insertion to removal or expulsion of foley bulb From time of documented insertion until the time of documented expulsion or removal, whichever came first, assessed up to 24 hours.
Secondary Presence of Chorioamnionitis Intrapartum fever (temp equal or greater than 38C) with no other identified cause at delivery
Secondary Use of Intravenous Analgesia During Labor Intravenous analgesia used between the start of induction and delivery at delivery
Secondary Number of Participants Used Neuraxial Analgesia During Labor Regional or neuraxial analgesia (labor epidural or spinal) used between the start of induction and delivery from start of induction to delivery
Secondary Number of Participants Used General Anesthesia for Delivery General anesthesia administered for delivery at delivery
Secondary Number of Participants With Meconium-stained Amniotic Fluid Identification of any meconium (green tinge) in the amniotic fluid before or during delivery by a healthcare provider's assessment of gross fluid color. At the time of rupture of membranes and at delivery
Secondary Terbutaline Use Administration of terbutaline, a tocolytic agent, for tetanic contractions with or without fetal heart rate decelerations at delivery
Secondary Number of Participants With Tachysystole 6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer at delivery
Secondary Number of Participants With Uterine Hyperstimulation Syndrome Tachysystole accompanied by fetal heart rate decelerations at delivery
Secondary Number of Participants With Excess Blood Loss Maternal excess blood loss is defined as >500ml for vaginal and >1000ml for cesarean delivery at delivery
Secondary Number of Participants With Blood Transfusion administration of blood products related to delivery blood loss at delivery
Secondary Number of Participants With Uterine Rupture spontaneous separation of myometrium in a previously intact, unscarred uterus at delivery
Secondary Number of Participants With Unplanned Hysterectomy unplanned removal of the uterus following delivery of the fetus at discharge from the hospital following delivery
Secondary Number of Participants With Postpartum Fever Fever recorded in the time after delivery but prior to discharge from the hospital, with clinical assessment of endometritis Following delivery and prior to discharge
Secondary Number of Participants With Umbilical Cord Blood pH <7.0 Arterial or venous cord blood pH defined as <7.0 at delivery
Secondary Number of Participants With an 5-minute Apgar Score Less Than 4 Appearance, Pulse, Grimace, Activity, Respirations - scored from 0 to 2 for each component, added to make a total score and used as an assessment of initial response to newborn resuscitation, lower scores associated with poor outcomes. Here defined as Apgar less than 4 at 5 minutes. 5 minutes after time of birth
Secondary Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No) Intubation with mechanical support or control of neonatal breathing in delivery room at delivery
Secondary Number of Participants Administered Neonatal Antibiotics and/or Neonatal Blood Cultures Administration of neonatal antibiotics and/or neonatal blood cultures From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
Secondary Number of Participants With Neonatal Sepsis Neonatal bacteremia as defined by bacterial growth in blood cultures From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
Secondary Number of Participants With NICU Admission Order Admission order to neonatal intensive care unit (NICU) placed between the time of delivery and infant discharge From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Terminated NCT02546193 - Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction N/A